Linked Life Data

17082590

Source:http://linkedlifedata.com/resource/pubmed/id/17082590

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17082590rdf:typepubmed:Citationlld:pubmed
pubmed-article:17082590lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0017349lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0003316lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0175631lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C1334510lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0385723lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C2827662lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:17082590lifeskim:mentionsumls-concept:C2348480lld:lifeskim
pubmed-article:17082590pubmed:issue10lld:pubmed
pubmed-article:17082590pubmed:dateCreated2006-11-3lld:pubmed
pubmed-article:17082590pubmed:abstractTextOver the past decade, many efforts have been made to identify MHC class II-restricted epitopes from different tumor-associated Ags. Melan-A/MART-1(26-35) parental or Melan-A/MART-1(26-35(A27L)) analog epitopes have been widely used in melanoma immunotherapy to induce and boost CTL responses, but only one Th epitope is currently known (Melan-A51-73, DRB1*0401 restricted). In this study, we describe two novel Melan-A/MART-1-derived sequences recognized by CD4 T cells from melanoma patients. These epitopes can be mimicked by peptides Melan-A27-40 presented by HLA-DRB1*0101 and HLA-DRB1*0102 and Melan-A25-36 presented by HLA-DQB1*0602 and HLA-DRB1*0301. CD4 T cell clones specific for these epitopes recognize Melan-A/MART-1+ tumor cells and Melan-A/MART-1-transduced EBV-B cells and recognition is reduced by inhibitors of the MHC class II presentation pathway. This suggests that the epitopes are naturally processed and presented by EBV-B cells and melanoma cells. Moreover, Melan-A-specific Abs could be detected in the serum of patients with measurable CD4 T cell responses specific for Melan-A/MART-1. Interestingly, even the short Melan-A/MART-1(26-35(A27L)) peptide was recognized by CD4 T cells from HLA-DQ6+ and HLA-DR3+ melanoma patients. Using Melan-A/MART-1(25-36)/DQ6 tetramers, we could detect Ag-specific CD4 T cells directly ex vivo in circulating lymphocytes of a melanoma patient. Together, these results provide the basis for monitoring of naturally occurring and vaccine-induced Melan-A/MART-1-specific CD4 T cell responses, allowing precise and ex vivo characterization of responding T cells.lld:pubmed
pubmed-article:17082590pubmed:languageenglld:pubmed
pubmed-article:17082590pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17082590pubmed:statusMEDLINElld:pubmed
pubmed-article:17082590pubmed:monthNovlld:pubmed
pubmed-article:17082590pubmed:issn0022-1767lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:RimoldiDonata...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:CerottiniJean...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:RomeroPedroPlld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:ThielemansKri...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:KwokWilliam...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:SpeiserDaniel...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:TiercyJean-Ma...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:TuyaertsSandr...lld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:BioleyGillesGlld:pubmed
pubmed-article:17082590pubmed:authorpubmed-author:JandusCamilla...lld:pubmed
pubmed-article:17082590pubmed:issnTypePrintlld:pubmed
pubmed-article:17082590pubmed:day15lld:pubmed
pubmed-article:17082590pubmed:volume177lld:pubmed
pubmed-article:17082590pubmed:ownerNLMlld:pubmed
pubmed-article:17082590pubmed:authorsCompleteYlld:pubmed
pubmed-article:17082590pubmed:pagination6769-79lld:pubmed
pubmed-article:17082590pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:meshHeadingpubmed-meshheading:17082590...lld:pubmed
pubmed-article:17082590pubmed:year2006lld:pubmed
pubmed-article:17082590pubmed:articleTitleMelan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.lld:pubmed
pubmed-article:17082590pubmed:affiliationDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland.lld:pubmed
pubmed-article:17082590pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17082590pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:2315entrezgene:pubmedpubmed-article:17082590lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17082590lld:entrezgene
lhgdn:association:32973lhgdn:found_inpubmed-article:17082590lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17082590lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17082590lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17082590lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17082590lld:pubmed